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Abstract
Introduction: Human epidermal growth factor 2 (Her2), a receptor tyrosine kinase, is overexpressed in breast
cancers. It has been successfully targeted by small molecule kinase inhibitors and by antibodies. Recent clinical
data show a synergistic response in patients when two antibodies, trastuzumab and pertuzumab, are given in
combination.
Methods: This unexpected effect is rationalized through computer models and molecular dynamic simulations by
hypothesizing that the two antibodies can co-localize on the same molecule of the Her2 extracellular domain.
Results: Simulations suggest that the clinical synergism observed for the two antibodies arises partly from
enhanced affinity that originates in cooperative interactions between these two antibodies when they are co-
localized on Her2 and “clamp” it; this may inhibit dimerization and possibly higher oligomerizations with
neighboring receptors. In the presence of trastuzumab, the receptor becomes highly plastic, especially domains I to
III, and this appears to promote increased association with pertuzumab. Further, the presence of pertuzumab
evokes novel interactions between the receptor and trastuzumab. Indeed, splicing out of this region in silico results
in a big reduction in the interactions of the antibody with the receptor.
Conclusions: If validated, these findings will bring about a new direction in the design of antibodies whereby
different epitopes on the same antibody may be targeted to lead to synergistic/cooperative inhibition and
contribute to generate more potent therapeutics and to increase clinical efficacy.
Introduction
ErbB receptors are the prototypical founders of the
growth factor receptor tyrosine kinase (RTK) family.
They are activated by the binding of different ligands
and are involved in the transmission of signals from the
extracellular space to the cytoplasm and nucleus of a
cell, thus orchestrating biological processes [1]. Among
the members of this family, which also includes the epi-
dermal growth factor receptor (EGFR or ErbB1), ErbB3,
ErbB4, Her2 or ErbB2 is homologous to, but distinct
from the others, since it is not activated upon ligand
binding. This ligand-independent activation makes Her2
the universal heterodimeric partner for each of the
other ErbB family members [2]. The architecture of
these receptors [3,4] reveals an extracellular domain
(made up of four subdomains), a single transmembrane
helix, and an intracellular domain (consisting of a juxta-
membrane region, a tyrosine kinase domain, and a C-
terminal tail harboring autophosphorylation sites that
serve as docking sites for adaptor proteins [5,6]). The
importance of the tight regulation of these receptors
and in particular Her2 is signified in human breast can-
cers, where Her2 is overexpressed by approximately 20
to 30% and this is normally associated with more
aggressive tumours and a poorer prognosis [7,8]. Due to
this active role in human cancers, a number of thera-
peutic approaches are currently under development to
block the effects of Her2 overexpression, including
kinase inhibitors (such as lapatinib) and monoclonal
antibodies (trastuzumab and pertuzumab) [9]. The anti-
Her2 monoclonal antibodyt r a s t u z u m a bb i n d st o
domain IV of Her2, a region that is not involved in
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plex manner [10,11]. In contrast, pertuzumab binds to
Her2 near the centre of the domain II dimerization arm
(Figure 1). The overlap between the pertuzumab epitope
and the probable heterodimer interface suggests steric
occlusion by physically blocking the formation of Her2-
containing heterodimers. Recent clinical observations
have demonstrated that combining trastuzumab and
pertuzumab together yields surprisingly synergistic
results in tumour inhibition (that is, the combined effect
of using the two molecules was far greater in effect than
when using either alone) during the treatment of Her2
positive breast cancers that progressed during prior tras-
tuzumab therapy [12]. Thiss u g g e s t sac o o p e r a t i v e
mechanism of inhibition that can lead to clinical
improvement in the treatment of these tumours.
We have used molecular modelling to develop a
mechanism that may partly explain this cooperative
effect. A simple model is that cooperativity could arise
from the physical co-localization of the two antibodies
on the same Her2 molecule, as has been previously
demonstrated for the insulin-like growth factor receptor
[13]. Models of the binary structures of Her2:trastuzu-
mab and Her2:pertuzumab were combined to create a
model of the ternary complex of Her2 and the two Fab
fragments of these antibodies. This system was subjected
to structural/energetic refinement followed by molecular
dynamics (MD) simulations (Additional file 1).
Methods
Building the models
The binary associations of Her2 and the two antibodies
have been experimentally characterized and are available
in the Protein Data Base (pdb entries: 1n8z[3] and 1s78
[14]). The electronic density of the C-terminal region of
the receptor is the Her2:pertuzumab complex is missing,
due probably to the high inherent flexibility of this part
of the structure. For the coordinates of the residues in
this region, we have assumed that this stretch will adopt
a conformation similar to the one found in the complex
with trastuzumab and have been so modeled. A few
other missing residues, located in loops, have been mod-
eled based on homologue structures. The ternary model
of the complex Her2 and the two Fab domains of these
antibodies, trastuzumab and pertuzumab, were manually
constructed using the coordinates of the previous mod-
els, after superposition on the backbone of the receptor
ectodomain.
MD simulations and binding energy calculations
We have used seven different systems for this study
(Additional file 1); the complete 3D model structure of
the complex (Her2-P-T), the receptor bound to trastu-
zumab (Her2-T) and pertuzumab (Her2-P), the apo-
receptor (Her2), the two independent antibodies (pert
and trast) and both antibodies co-localized as they are
found in the complex (Abs). All these systems have
been refined using several energy minimization and
short MD simulation cycles in order to equilibrate the
structures after which they were subjected to the pro-
duction phases of MD simulation (around 18 to 20 ns
each) in explicit water, as detailed. The AMBER
(Assisted Model Building with Energy Refinement) 9
package [15] together with the ff99 force field [16] was
used. The protonation states of the residues were
assigned using PDB2PQR [17], after which the systems
were surrounded with a box of TIP3 or Transferrable
Interaction Potential 3 water molecules that result in an
8 Å layer of water molecules around the proteins and
neutralized by the necessary numbers of Cl-or Na+
counter-ions using the t-leap module of AMBER 9. The
solvated systems were then subjected to a minimization
phase, mainly by the steepest descend method and small
number of conjugate gradient steps, in order to remove
bad contacts. After that a 50 ps heating phase was car-
ried out, where the proteins were heated from 0 to 300
K, followed by another 50 ps phase density equilibration
at a constant pressure of 1 atm. A final 2 ns uncon-
strained MD simulation was carried out. The production
runs were extended to around 20 ns at constant tem-
perature using a Langevin thermostat [18] and constant
pressure (1 atm) by coupling to a Berendsen barostat
These two queries do not need to be address since these
are mathematical methods and not devices [19]. The
particle mesh Ewald (PME) method [20] was used with
a direct-space non-bonded cutoff of 8 Å to account for
long range interactions. Covalent bond lengths to hydro-
gen atoms were constrained using the SHAKE algorithm
[21], which allowed a time step of 2 fs for all the MD
simulations. Snapshots in the interval of 8 to 16 ns were
extracted for further processing. The analysis was car-
ried out using functionalities in the ptraj module of
AMBER 9, the module Bio3D [22] of R and Dyndom
[23]. The PyMOL molecular viewer, a software package
[24] was used for visualizing and generating the figures.
The binding free energy ΔGbind of the different sys-
tems was calculated according to the so-called Molecu-
lar Mechanics/Generalized-Born Surface Area (MM/
GBSA) procedure [25]. Here ΔGbind denotes the contri-
butions from the molecular mechanics (MM) energies
of the molecules, and originates in contributions from
internal energies, electrostatics (ΔGELE)a n dv a nd e r
Waals (ΔGVDW) contributions. These terms have been
calculated using the mm_pbsa module of AMBER 9.
The polar component was evaluated with the General-
ized-Born (GB) approach. In this approach, the non-
polar contribution to the solvation energy was calculated
as ΔGNP = g (SASA) + b, in which g = 0.00542 kcal/Å, b
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face area estimated with LCPO (linear combination of
pairwise overlaps) method [26] as implemented in
AMBER. While the real free energy of a system also
includes contributions from the entropies, given the
large sizes of the systems studied here, computations of
entropies were prohibitive and hence could not be car-
ried out. However, the free energies computed here
have been averaged over several conformations gener-
ated through MD simulations, and hence the effects of
entropy to some extent are implicitly included in the
current calculations.
Essential dynamics analysis and Dyndom analysis of Her2
and its antibodies
Essential dynamics [27,28] have been widely used for fil-
tering large scale concerted fluctuations from an ensemble
of conformations, like those obtained from MD simula-
tions [29]. The method is comparable to a principal com-
ponent analysis, and it is based on the construction of the
diagonalized covariance matrix containing the atomic fluc-
tuations. We have performed a standard essential
dynamics (or Principal Component Analysis, PCA) analy-
sis in order to identify the most relevant motions occur-
ring in the receptor in the different bound states
considered on the MD simulations carried out in this
study (Additional file 2); all the covariance matrices have
been calculated taking the apo receptor as a reference
structure. This yields a set of eigenvectors in a 3N-dimen-
sional space, and eigenvalues, reflecting the magnitude of
the fluctuations along the corresponding eigenvectors.
Each eigenvector describing a collective motion can be
represented by two structures, one at the maximum value,
the other at the minimum value of the collective variable
when the trajectory is projected onto it. These two struc-
tures thus generated for the first eigenvector of each tra-
jectory were used as input for the program DynDom [23],
using default parameters, in order to determine dynamic
domains, hinge axes and hinge-bending regions.
Results and discussion
Conformational space of Her2 in different bound forms
Simulations show that the ectodomain of Her2 adopts
various conformations, depending on its bound state.
The binary states (when complexed to trastuzumab or
pertuzumab) are more stable compared to the apo or the
ternary complex (Additional file 3). This could stem from
the high intrinsic flexibility of the apo receptor or/and
the ternary complex. Although a complete understanding
of the behaviour of such a receptor demands the full-
length structure, we believe that the models used here
represent valid starting structures for the type of analyses
carried out in this study. As expected, the presence of an
antibody immobilizes its corresponding epitope
(Additional file 4). The largest fluctuations in the pertu-
zumab binding region (ranging from 240 to 300) and in
the trastuzumab epitope (around 550 to 600) are seen in
the apo state or in the Her2:trastuzumab or Her2:pertu-
zumab complexes respectively. Interestingly the dimeri-
zation arm, a b h a i r p i ni nd o m a i nI It h a tp r o t r u d e sf r o m
the rest of Her2, together with the spatially adjacent
regions, undergoes enhanced fluctuations when trastuzu-
mab binds. This may reinforce the fact that the Her2:
trastuzumab complex can actually promote the associa-
tion of Her2 with other members of the ErbB family.
We have also investigated the flexibility of the antibo-
dies and the stability of their binding interfaces with
Her2. In general, the complementary determining
regions (CDR) exhibit smaller fluctuations in compari-
son to the rest of the antibody; whereas regions far from
the receptor’s influence remain extremely flexible. In the
ternary complex, the C-terminal half of the light chain
of pertuzumab shows an increased flexibility, induced by
the presence of trastuzumab (Additional file 4). Trastu-
zumab shows a more complicated pattern. When only
trastuzumab is present in the complex, the whole anti-
body shows a high flexibility, with the exception of the
CDR for the light chain. In the ternary complex, the
light chain undergoes the largest fluctuations in the
region interacting with the receptor binding epitope;
however the most relevant difference is an attenuation
in the mobility of the N-terminal half of the heavy chain
due to the proximity of one of the disulphide-bonded
modules of domain II, which in turn shows lower flex-
ibility (residues 310 to 325; see section below on new
epitopes). We can conclude that the dynamics of pertu-
zumab seem to be regulated mainly by the binding to
the receptor; while for trastuzumab, the co-binding of
the second antibody has a significant effect. When the
two antibodies are analysed in the absence of the recep-
tor, trastuzumab per se seems more flexible than pertu-
zumab, which can be the origin of the more complex
dynamics observed for the systems including this anti-
body. These intricate changes and regulation between
the different components of the system reflect the
importance of flexibility and could point to “allosteric”
changes in explaining the in vivo synergistic effect.
Uncovering new epitopes in Her2
The analysis of the interactions between Her2 and the
two antibodies reveals that the perturbation of the crys-
tallographically observed interfacial region of Her2 is
small during the simulations of the binary complexes
(Additional file 5). However, the co-localization of the
two Abs on Her2 surprisingly triggers the formation of
additional and novel contacts of Her2 with trastuzumab;
these lie outside of its epitopes (Figure 1). This b-hair-
pin loop region, termed the pertuzumab-induced
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pertuzumab (in orange) -induced trastuzumab (in black) epitope that emerges during the course of the MD simulations of Her2 ectodomain (in
red-blue electrostatic surface where red represents regions of acidity and blue represents regions of basicity) in presence of trastuzumab and/or
pertuzumab. (A) Her2:trastuzumab complex structure at the beginning of the simulation(time = 0 ns) showing no contact between trastuzumab
and the new epitope and (B) snapshot taken during the MD simulation (time = 15 ns) showing interactions between trastuzumab and the new
epitope; (C) dynamic Ca-Ca contact matrix (representing the distance between each pair of residues comprising the three dimensional structure
of protein complex), the data from both pertuzumab and trastuzumab co-localized on Her2 are shown below the diagonal; the data from the
Her2-trastuzumab complex are shown above the diagonal. Trastuzumab has been coloured in black; while pertuzumab is shown in orange. This
plot shows the occurrence of interactions between the heavy chain of trastuzumab (see vertical axis) and the region of the ectodomain around
310 to 330 (see the horizontal axis). During the course of simulation, when pertuzumab is bound to Her2:trastuzumab these contacts are formed,
in contrast to the simulation where only Her2:trastuzumab are present (comparison with the same region above the diagonal) where these
contacts are absent.
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proximity to the dimerization arm. The requirement of
the co-localization of the two Abs for the formation of
this new epitope is revealed in the minimum distance
matrices for all the Ca atoms for the receptor and tras-
tuzumab in the simulations of the binary and ternary
complexes (see Figure 1C upper and lower diagonal of
the matrix, respectively). This can also be observed from
the reported distances between two residues in this
novel epitope and residues at the interface in trastuzu-
mab (Additional file 6). For this epitope to emerge in
the Her2:trastuzumab interface, the presence of pertuzu-
mab is strictly required. This novel association is mainly
driven by long-range interactions, and could be the ori-
gin of the observed synergism.
Quantification of synergism between pertuzumab and
trastuzumab
The MM-GBSA (molecular mechanics Generalized Born
surface area) [25] is regularly employed to obtain esti-
mates of the free binding energy of large systems and
these are largely reasonable [30-32]. These only refer to
the enthalpic component of the overall free energies of
binding because computations of entropies of such large
systems are prohibitively expensive. The derived associa-
tion energetics of trastuzumab and pertuzumab to Her2
are shown in Table 1; the computed values are very
large as is the case with computations involving large
systems; indeed in comparison the binding of trastuzu-
mab to the extracellular domain of Her2 and to Her2
positive cells ranges from approximately -12.5 to -14
kcal/mol [33]. However, despite being large, qualitative
analyses of the differences in the computed binding
energies are very useful in ranking interactions. Our
findings suggest (the more negative an energy, the more
stable the associated system):
- trastuzumab has a higher affinity for apo Her2 than
pertuzumab (Figure 2A); this arises from stronger elec-
trostatic and van der Waals interactions between trastu-
zumab and Her2 (the net charge on Her2 is -15, while
on trastuzumab and pertuzumab it is +6 and +5
respectively); the buried area at the interface is approxi-
mately 1,675 and approximately 1,530 Å
2 for trastuzu-
mab and pertuzumab, respectively
- a marked gain in affinity when both Abs are bound
simultaneously to the receptor (synergism). This effect
arises mainly from the interactions between these two
antibodies upon co-localization, with a difference of
approximately 27 kcal/mol between isolated and simul-
taneously bound antibodies (Figure 2C).
The computed energetics within these thermodynamic
cycles suggest a sequential mechanism, where the initial
binding involves trastuzumab (Figure 2A) followed by
the binding of pertuzumab (Figure 2B). This seems to
be partly driven by the conformational changes triggered
upon the binding of trastuzumab that enhance pertuzu-
mab binding (Figure 3) and the new additional contacts
formed between trastuzumab and Her2. The enhanced
interactions that accrue when the two antibodies are co-
localized on Her2 leading to the cooperative effects, may
provide a partial explanation for the clinically observed
synergy. In order to support the effect of this newly
revealed pertuzumab-induced trastuzumab epitope, we
have constructed an in silico truncated form of Her2,
where this b-hairpin has been deleted (T323C-AEDG-
T328C), and we find that the binding energetics
undergo a marked destabilization (Table 1).
Abs-induced bending of the Her2 ectodomain
Principal Component Analysis (Additional file 2) com-
bined with dynamical domain motion analysis using Dyn-
D o ms u g g e s t st h a td o m a i n sIt oI I I( r e s i d u e s1t o4 8 0 )
generally behave as a rigid body, with hinge regions vary-
ing in their location in domain IV, depending on the bind-
ing partner of the receptor (Additional files 7 and 8). Two
different motions are detected in the apo state of Her2; the
first one involves a shearing motion between the stalk por-
tion of the receptor and the large rigid-body unit; whereas
the second one corresponds to a hinge motion within
domain IV. The overall change in conformation involves a
large conformational space scanned by the dimerization
arm with respect to the membrane surface (with an angle
Table 1 In silico binding free energy for the association of Her2 ectodomain and the two antibodies
ΔGELE ΔGVDW ΔGGB ΔGNP Total ΔG
Her2-T < -Her2 + trast -841.6 -116.3 -197.8 -14.8 -1,144.6
Her2-P < -Her2 + pert -490.5 -55 -480.1 -4.3 -1,095.7
Her2-P-T < -Her2 + trast + pert -1,028.8 -102.6 -217.7 -11.5 -1,438.8
Her2-P-T < -Her2 + Abs -1,374.4 -114.9 730.4 -17.6 -851.0
Her2-trunc-P-T < -Her2-trunc + trast + pert -1,044.3 -149.4 469.2 -20 -725.0
Binding free energy components (kcal/mol) for the association of Her2 to pertuzumab and trastuzumab calculated using MM-GBSA method using MD snapshots
extracted from independent simulations.
Her2-T, Her2-trastuzumab; trast: trastuzumab; Her2-P, Her2-pertuzumab; pert, pertuzumab; Her2-P-T, Her2-pertuzumab-trastuzumab; Abs, antibodies (here
specifically it refers to both pertuzumab and trastuzumab); Her2-trunc, truncated form of Her2; ΔGbind, binding free energy; MM/GBSA, molecular mechanics/
Generalized-Born surface Area; ΔGELE, electrostatics energy; ΔGVDW, van der Waals energy; GB, Generalized-Born; ΔGNP, non-polar energy
Fuentes et al. Breast Cancer Research 2011, 13:R54
http://breast-cancer-research.com/content/13/3/R54
Page 5 of 9of approximately 50° for the parallel and approximately 78°
for the motion perpendicular to the membrane), which
represents periscope-like movements that this receptor
might execute in search of binding partners. In the case of
the ternary complex, the binding of trastuzumab causes a
shift in the hinge region along domain IV. This is asso-
ciated with small swivelling motions across an axis ortho-
gonal to the membrane; if the receptor lies parallel to the
membrane [34] then this would represent “out of the
membrane” motions. The dimerization arm spans approxi-
mately 16 Å in comparison to the apo form which covers
approximately 33 Å (measured from the Ca of the atom
(Pro252) at the base of this motif). In contrast, in the
binary states, the pattern of motion differs: domain IV
behaves as a rigid body and only one hinge region is appar-
ent. When trastuzumab is bound, a hinge motion is
observed (18°) between the bulky domain I-to-III and
domain IV (crystallographic data show approximately 7° in
the angle subtended between domains III and IV); the
Her2:pertuzumab complex undergoes more complex
motions. The deletion in the truncated mutant results in
attenuation of two-body rotations along the parallel axis
(from 48° in the “full-length” receptor to approximately 28°
in the truncated form). In contrast, the bound form of this
truncated receptor undergoes a hinged motion spanning
approximately 20°.
Figure 2 Thermodynamic cycles to study the cooperative binding of Her2 to trastuzumab and pertuzumab. (A) The cycle with the
energy estimations calculated from the independent association simulations. (B) The cycle analysed using the conformations of receptor and
binary complexes from the co-localized interaction simulations. The energetics for the binary complexes have been obtained from the ternary
complex of Her2:pertuzumab:trastuzumab complex, in an attempt to account for the influence of the other antibody when both are co-localized.
(C) The cycle representing the gain in energy between the binding of the two antibodies to each other in an isolated system or when co-
localized onto the structure of the receptor. The ectodomain of Her2 has been coloured in green, while trastuzumab and pertuzumab are
represented in black and orange, respectively. The differences in free energy binding estimated for every system are shown. The computations
were for the following schemes: A) her2-trastuzumab < -her2+ trastuzumab; her2-trast-pert < -her2-trast + pertuzumab her2-trast + pertuzumab
< -her2+ trastuzumab + pertuzumab her2-pertuzumab < -her2+ pertuzumab; her2-trast-pert < -her2-pert + trastuzumab. B) her2-trastuzumab
(extracted from her2:pert:trast) < -her2+ trastuzumab; her2-trast-pert < -her2-trast (extracted from her2-pert:trast) + pertuzumab her2-pertuzumab
(extracted from her2:pert:trast) < -her2+ pertuzumab; her2-trast-pert < -her2-pert (extracted from her2-pert:trast) + trastuzumab. C) Abs (extracted
from her2:pert:trast) < -pertuzumab + trastuzumab; Abs < -pertuzumab + trastuzumab.
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Her2 ectodomain adopts in the different conditions ana-
lysed here indicates that domains I, II and III adopt a
relatively fixed interdomain relationship, but their rela-
tive orientations with respect to domain IV varies con-
siderably (up to approximately 80°), and appear to be
pivoted across the region 504 to 532 that lies between
domains III and IV. This is indicative of the plasticity
inherent in these receptors and suggests that the extra-
cellular domain can swivel quite considerably across
domain IV that itself is constrained by being embedded
partly in the membrane.
Conclusions
In summary, MD simulations suggest that the clinical
synergism observed for the two antibodies arises partly
from an enhanced affinity that originates in cooperative
interactions between these two antibodies when they are
co-localized on Her2 and “clamp” it; this may inhibit
dimerization and possibly higher oligomerizations with
neighbouring receptors. In the presence of trastuzumab,
the receptor becomes highly plastic, especially domains
I-III, and this appears to promote increased association
with pertuzumab. While combining antibodies is a fea-
ture that increasingly appears to have major effects in
therapy (see, for example, the work of Chao and co-
workers [35], which combines two different antibodies
against two different cell surface molecules for treat-
ment of non-Hodgkin’s lymphoma), a model incorporat-
ing the idea that two antibodies bind to the same
receptor, albeit at distinct epitopes, is relatively new;
indeed there has been only one report of such a feature
as highlighted for targeting the IGF-1 receptor [13].
These findings could be tested, for example, in 2D and
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Figure 3 Structural changes on Her2 ectodomain upon binding of trastuzumab and/or pertuzumab. To understand the structural
changes that occur as a result of the binding of the two antibodies, we analyse the conformational transition/populations using cross 2D-RMSD
plots (a plot of RMSD vs RMSD) of the ectodomain of Her2 in the trajectory of the ternary complex of Her2:pertuzumab:trastuzumab and the
different apo and binary trajectories. The latter were fitted onto the full receptor structure, except the pertuzumab epitope region, and the rmsd
has been calculated for the Ca atoms using the initial structure of the ternary complex simulation as reference. These maps reveal the
differences of the various conformations sampled during the simulation with respect to the ternary complex. Different populations of structures
are observed in the plots, with structures closest to the conformation adopted for the receptor at the beginning of the ternary simulations
shown in blue, to those that are most altered in red (the largest variations are up to approximately 10 Å RMSD). The binding of trastuzumab
displaces the conformation of the receptor towards that found in the ternary complex (see plot at the left and density distribution for such a
complex). These conformational changes enhance the binding of pertuzumab and thus the affinity of the two antibodies for the receptor is
increased, as shown in Table 1, leading to cooperativity.
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mab efficacy [36,37]. While we await experimental
investigations of this novel mechanism in Her2, if vali-
dated, it offers routes towards the design of new antibo-
dies whereby combinations of trastuzumab and
pertuzumab (or parts thereof) may be constructed that
have the potential to generate therapeutics with much
higher affinities and hopefully efficacies. The technology
of generating hybrid antibodies or bi-specific antibodies
[38] is known; however, this technique has been used
for linking two antibodies that target different mole-
cules. In contrast our hypotheses open the avenue for
linking two antibodies that target distinct epitopes on
the same molecule.
Additional material
Additional file 1: Supplemental Figure S1. Cartoon representation of
all the systems involved in the study; A) Apo Her2; B) binary complex
between Her2:pertuzumab; C) binary complex between Her2:
trastuzumab; D) ternary complex between Her2:pertuzumab:trastuzumab;
E) pertuzumab; F) trastuzumab; G) “binary” interaction between
trastuzumab:pertuzumab. Trastuzumab has been coloured in black; while
pertuzumab is shown in orange.
Additional file 2: Supplemental Figure S2. The characterization of
the collective protein dynamics have been analyzed using Principal
Component Analysis (PCA). PCA is a statistical method that highlight
similarities and differences in a complex data set by reducing the
number of dimensions without losing much of the information. In MD
simulations, the application of PCA can separate the configurational
space into two subspaces; the essential one containing the functionally
important correlated motions (comprising only few degrees of freedom
or eigenvectors) and the irrelevant subspace with the independent
Gaussian fluctuations with little functional relevance. In this study, PCA
has been performed on an ensemble of conformations derived from the
different MD simulations. Results of PCA obtained from the
diagonalization of the atomic displacement correlation matrix of Ca
atoms of the ectodomain from six of the MD simulations carried out in
this study (using standard Euclidean distances) are shown here. The
resulting Principal Components (PCs) are sorted according to their
contribution to the total fluctuation along the ensemble of
conformations, and only a small subset of these PCs are necessary to
describe the great majority of the total atomic displacements which
capture the essential dynamics of the conformational changes occurring
in the system (the above so-referred essential subspace). Every figure
contains the percentage of the cumulative eigenvalues as a function of
the number of eigenvectors considered. The inset includes the
projection on the first two eigenvectors of the coordinates extracted
from the time interval of 8 to 16 ns. Every figure represents the
coordinates for the ectodomain of Her2 from the following simulations:
(A) apo Her2; (B) Her2:pertuzumab:trastuzumab; (C) Her2:pertuzumab; (D)
Her2:trastuzumab; (E) apo truncated Her2; (F) truncated Her2:
pertuzumab:trastuzumab. The application of PCA on data obtained from
MD simulations provides a useful way of detecting global, correlated
motions of the system that are separate from the tightly-constrained
harmonic motions of more constrained atoms. The structures projected
on the first eigenvectors have facilitated our understanding of the
dynamics of the six systems analysed here (see Supplementary Figure
S6).
Additional file 3: Supplemental Figure S3. Ca RMS deviation with
respect to the starting frame of the 2-ns equilibration phase versus
time. (A) apo Her2 simulation; (B) ternary complex Her2:trastuzumab:
pertuzumab; (C) binary complex Her2:trastuzumab; (D) binary complex
Her2:pertuzumab. The top panel for all the plots represent the RMSD for
the whole system; this is broken into the different components in the
association in the bottom plots.
Additional file 4: Supplemental Figure S4. RSM fluctuation plots and
cartoon figures for the different systems of Her2 in the apo-and
holo-states with pertuzumab and trastuzumab. A) RMS fluctuations
for trastuzumab-containing systems (top); RMS fluctuations for
pertuzumab-containing systems (middle panel) and RMS fluctuations for
the ectodomain of the receptor in the four different MD simulations; B)
putty/sausage cartoon representation for apo-receptor (right), Her2 in
complex with the two antibodies, with trastuzumab and with
pertuzumab (from top to bottom) and colored accordingly to the
fluctuation values per residue. The complementarity determining regions
(CDR) of both antibodies have been marked in the plot with blue boxes.
The trastuzumab and pertuzumab epitopes have been highlighted in
shaded boxes in grey and cream and black, respectively.
Additional file 5: Supplemental Table S1. Ca-Ca distances for the
residues at the receptor:Ab interfaces detected along the
simulations between Her2 and the two Abs: pertuzumab and
trastuzumab. The different shading boxes indicate the CDR of the
antibodies.
Additional file 6: Supplemental Figure S5. Interactions between the
two antibodies and new epitope revealed in the MD simulations.
(A) Density distributions for the intermolecular Ca-Ca distance between
Glu294 and Asp295 (labeled in the Figure C) in the pertuzumab-induced
trastuzumab epitope of the receptor and their putative interacting
residues at the interface in trastuzumab. The dashed lines represent the
population in the Her2:pertuzumab:trastuzumab simulation, while the
straight lines show the distribution found in the Her2:trastuzumab
simulation. (B) Density distribution for the intermolecular Ca-Ca distance
between residues in the different Abs. In horizontal lines the average
distance for the ternary (red) and binary (blue) simulations are shown. (C)
Schematic representation of the residues for which the distances have
been measured. The color coding is the same as in Figure S1.
Additional file 7: Supplemental Figure S6. Cartoon representation of
the maximum and minimum conformations of Her2 along the first
eigenvector extracted from the PCA analysis and colored according
to the Dyndom output (see Additional file 8) for the following
simulations: (A) apo Her2; (B) Her2:pertuzumab:trastuzumab; (C) Her2:
pertuzumab; (D) Her2:trastuzumab; (E) apo truncated Her2; (F) truncated
Her2:pertuzumab:trastuzumab. All the models were fit onto the last 20
residues of the ectodomain.
Additional file 8: Supplemental Table S2. Dynamical domains and
hinge bending residues determined by the program DYNDOM for the
superposition of the Her2 receptor of the trajectories of this domain in
the apo, dimeric and trimeric forms with trastuzumab and pertuzumab.
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